You are here

Article Text

Article menu
Download PDFPDF
ABN Abstracts 2016
ABN Annual Meeting, 17–19 May 2016, The Brighton Centre, Brighton
155
PREGNANCY OUTCOMES IN ALEMTUZUMAB-TREATED PATIENTS WITH RRMS
  1. David Rog1,
  2. Christina Chambers2,
  3. Pamela McCombe3,
  4. Susana Otero4,
  5. Kerstin Hellwig5,
  6. David Margolin6,
  7. Karthinathan Thangavelu6,
  8. Jiwon Oh7,
  9. on behalf of the CAMMS223 CARE-MS I and CARE-MS II Investigators1
  1. 1 Salford Royal NHS Foundation Trust, Salford, UK
  2. 2 University of California San Diego, La Jolla, CA, USA
  3. 3 The University of Queensland, Brisbane, Australia
  4. 4 Multiple Sclerosis Center of Catalonia, Barcelona, Spain
  5. 5 St Josef Hospital, Ruhr University Bochum, Germany
  6. 6 Sanofi Genzyme,Cambridge, MA, USA
  7. 7 St. Michael's Hospital, University of Toronto, Toronto, Ontario, CA

Abstract

Here we provide updated pregnancy outcomes in alemtuzumab-treated female patients in phase 2 (CAMMS223 [NCT00050778]) and phase 3 (CARE-MS I [NCT00530348], CARE-MS II [NCT00548405]) studies. Patients received annual treatment courses of alemtuzumab and could enter an extension study (NCT00930553), with as-needed alemtuzumab retreatment (≥1 year apart). Pregnant/lactating patients were treatment-ineligible but remained on study for safety follow-up. As of July 1, 2015, 193 pregnancies occurred in 136 of 972 alemtuzumab-treated female patients; 167 were completed, 16 were ongoing, and 10 had unknown outcomes. Of completed pregnancies, 110 (66%) were live births with no congenital abnormalities or birth defects among 94 patients (at conception: mean age, 31.5 years; mean EDSS, 1.7; mean time since initial MS relapse, 6.6 years; mean time since last MS relapse, 3.5 years; mean time from previous alemtuzumab infusion, 27.9 months). There were 37 (22%) spontaneous abortions, 19 (11%) elective abortions, and 1 (0.6%) previously reported stillbirth. In alemtuzumab MS clinical studies, the most common pregnancy outcome was full-term live birth, with no evidence of teratogenicity to date. The rate of spontaneous abortion with alemtuzumab was comparable with rates observed in other MS patients and general populations. Ongoing surveillance is needed.

Study supported by Sanofi Genzyme and Bayer Healthcare Pharmaceuticals.

https://doi.org/10.1136/jnnp-2016-315106.155

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.